Dated: June 24, 2014.

#### Sarah L. Glavin.

Deputy Director, Office of Science Policy, Analysis, and Communications, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.

[FR Doc. 2014-15669 Filed 7-2-14; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

# Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Plasticity, Neuroprotection, and Function in Brain Injury and Cognitive Impairment.

Date: July 24, 2014.

Time: 11:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Alessandra C Rovescalli, Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Rm 5205 MSC7846, Bethesda, MD 20892, (301) 435–1021, rovescaa@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Plasticity, Neuroprotection, and Function in Brain Injury and Addiction.

Date: July 25, 2014.

Time: 10:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Alessandra C Rovescalli, Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Rm 5205 MSC7846, Bethesda, MD 20892, (301) 435–1021, rovescaa@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Mechanisms of Neurodegenerative Disease and Injury. Date: July 25, 2014.

Time: 1:00 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Christine A Piggee, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4186, MSC 7850, Bethesda, MD 20892, 301–435– 0657, christine.piggee@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Biology.

Date: July 28, 2014.

Time: 8:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Charles Morrow, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6202, MSC 7804, Bethesda, MD 20892, 301–451–4467, morrowcs@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Project: Structure and Function of 3–Osulfated Heparan Sulfate.

Date: July 29-30, 2014.

Time: 7:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kathryn M Koeller, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4166, MSC 7806, Bethesda, MD 20892, 301–435– 2681, koellerk@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Adverse Drug Reactions in Children.

Date: July 29, 2014.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Janet M Larkin, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1102, MSC 7840, Bethesda, MD 20892, 301–806– 2765, larkinja@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Project: A Resource for Biomedical Mass Spectrometry.

Date: July 29–31, 2014.

Time: 5:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

*Place:* The Chase Park Plaza, 212 N. Kingshighway, St Louis, MO 63108.

Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5181, MSC, Bethesda, MD 20892, belangerm@ csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS).

Dated: June 27, 2014.

### Anna Snouffer,

Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2014–15582 Filed 7–2–14; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

## National Library of Medicine Notice of Meetings Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the Board of Scientific Counselors, Lister Hill National Center for Biomedical Communications, September 11, 2014, 9:00 a.m. to September 12, 2014, 11:00 a.m., National Library of Medicine, Building 38, Board Room, 8600 Rockville Pike, Bethesda, MD 20892 which was published in the **Federal Register** on June 9, 2014, 79 FR 110, Page 32968.

The meeting of the Board of Scientific Counselors, Lister Hill National Center for Biomedical Communications, will be held on September 18–19, 2014 instead of September 11–12, 2014, at 9:00 a.m. and will end at 11:00 a.m. The meeting is partially closed to the public.

Dated: June 27, 2014.

## Michelle Trout,

Program Analyst, Office of the Federal Advisory Committee Policy.

[FR Doc. 2014–15557 Filed 7–2–14; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

## Notice of National Institutes of Health Workshop on the Enrollment and Retention of Participants in NIH-Funded Clinical Trials

**SUMMARY:** The National Institutes of Health (NIH) is conducting a workshop with interested stakeholders in order to hear perspectives on issues related to the enrollment and retention of research participants in NIH-funded clinical

trials. The workshop will be open to the public.

**DATES:** The workshop will be held on Friday, July 25, 2014, from 8:15 a.m. to 5:45 p.m., in the NIH Porter Neuroscience Research Center, 35 Convent Drive, Bethesda, Maryland 20892.

### FOR FURTHER INFORMATION CONTACT:

Registration and workshop information is available at the NIH Office of Science Policy (OSP) Web site (http://osp.od.nih.gov). OSP's mailing address is 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. Additional questions about the workshop may be directed to the office by calling 301–436–9838, or by emailing OCRBP-OSP@od.nih.gov.

SUPPLEMENTARY INFORMATION: The NIH's ability to improve the efficiency and effectiveness of its clinical trials is critical to the agency's mission to foster research strategies that protect and improve human health. The goal of the workshop is to explore strategies to enhance enrollment, recruitment, and retention of participants in clinical trials.

The meeting agenda covers a range of topics related to the enrollment and retention of clinical trial participants, including: current challenges in clinical trial participant enrollment; cultural and social considerations in clinical trial participant enrollment and outreach; recruitment and outreach considerations for underrepresented and vulnerable populations; roles for public foundations in clinical trial participant enrollment and retention; public private partnerships to improve patient and public awareness and engagement; models to identify and support clinical trial participants; and strategies for tracking and monitoring clinical trial participation and post-trial communication. A full meeting agenda will be available prior to the workshop at the NIH OSP Web site (http:// od.osp.nih.gov).

The meeting will be open to the public, with attendance limited to the space available. Instructions for preregistration (required) are available on the NIH OSP Web site (http://osp.od.nih.gov). Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting

in advance of the meeting.

In the interest of security, the NIH has instituted stringent procedures for entrance onto its Bethesda campus. All vehicles, including taxis, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will

be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit. For more information about the security measures at the NIH, please visit the Web site at <a href="http://www.nih.gov/about/visitorsecurity.htm">http://www.nih.gov/about/visitorsecurity.htm</a>.

Dated: June 27, 2014.

#### Lawrence A. Tabak,

Principal Deputy Director, National Institutes of Health.

[FR Doc. 2014-15681 Filed 7-2-14; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

# National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, NHLBI Opportunities for Collaborative Research at the NIH Clinical Center.

Date: July 31, 2014.

Time: 12:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Room 7178, Bethesda, MD 20892–7924, (Telephone Conference Call).

Contact Person: William J Johnson, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7178, Bethesda, MD 20892–7924, 301–435– 0725, johnsonwj@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS). Dated: June 27, 2014.

#### Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014-15556 Filed 7-2-14; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Substance Abuse and Mental Health Services Administration

# Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given for the meeting of the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Prevention National Advisory Council (CSAP NAC) on July 7, 2014.

The meeting will include the review, discussion and evaluation of grant applications reviewed by the Initial Review Group, and involve an examination of confidential financial and business information as well as personal information concerning the applicants. Therefore, this meeting will be closed to the public as determined by the SAMHSA Administrator, in accordance with Title 5 U.S.C. 552b(c)(4) and (6) and (c)(9)(B) and 5 U.S.C. App. 2, Section 10(d).

Substantive program information, a summary of the meeting, and a roster of committee members may be obtained either by accessing the SAMHSA Committee's Web site after the meeting, <a href="http://nac.samhsa.gov/">http://nac.samhsa.gov/</a>, or by contacting the council's Designated Federal Officer.

Committee Name: Substance Abuse and Mental Health Services, Administration Center for Substance Abuse Prevention, National Advisory Council.

Date/Time/Type: July 7, 2014 from 2pm to 3pm EDT: (CLOSED).

Place: Teleconference.

Contact: Matthew J. Aumen, Designated Federal Officer, SAMHSA CSAP NAC, 1 Choke Cherry Road, Rockville, Maryland 20857, Telephone: 240–276–2419, Fax: 240–276–2430 and Email: matthew.aumen@samhsa.hhs.gov.

### Cathy J. Friedman,

Public Health Analyst, Substance Abuse and Mental Health, Services Administration.

[FR Doc. 2014–15568 Filed 7–2–14; 8:45 am]

BILLING CODE 4162-20-P